// App-Quantinova.ai

DXT30 : The Occurrence of Infusion-Related Reactions Among Patients with Multiple Sclerosis Undergoing Treatment with Ocrevus (Ocrelizumab) in a Community Setting Receiving a Standard Pre-Infusion Protocol.

Researchers

Presenter

  • Hollis O'Nell-Meyer

Principal Investigators

  • Jennifer A. Ruiz

  • Elizabeth S Gromisch

  • Lindsay Neto

  • Peter Wade

Medical Centers

  • Mount Sinai Rehabilitation Hospital, Trinity Health Of New England

  • Frank H. Netter Medical School at Quinnipiac University

  • University of Connecticut School of Medicine

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • Ocrelizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved